Predicted to have citrate transmembrane transporter activity; sodium:dicarboxylate symporter activity; and succinate transmembrane transporter activity. Predicted to be involved in citrate transport. Predicted to localize to the integral component of membrane; INTERACTS WITH 2-hydroxypropanoic acid; aflatoxin B1; amiodarone.
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC13A4 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC13A4 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC13A4 mRNA
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051101]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051101]|See cases [RCV000051101]
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000054172]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000054172]|See cases [RCV000054172]